SCHEMBL3011035

SCHEMBL3011035

Cc1cc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)c(C)c1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DNM1L O00429 9/20 0.36
GBA1 P04062 1/20 0.36
KMT2A Q03164 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 2/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MEN1 O00255 2/20 0.33
HSD11B1 P28845 1/20 0.33
HSD17B2 P37059 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015354 0.92 HSD11B1 (0.36) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3015515 0.91 GBA1 (0.42) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3012528 0.90 DNM1L (0.37) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3015958 0.89 KMT2A (0.38) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3020585 0.89 DNM1L (0.37) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3007065 0.89 SMN1; SMN2 (0.39) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3008086 0.87 GBA1 (0.37) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3022020 0.87 DNM1L (0.36) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3014372 0.87 GBA1 (0.41) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3016045 0.86 DNM1L (0.34) DNM1LGBA1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA DNM1L 180/4885GBA1 4/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.